Australian Biotech Stock News

Australian Clinical Labs (ASX:ACL) is in focus after reporting half year 2025 results that show lower net income while sales remained close to prior levels, and the company also declared a fully franked interim dividend. See our latest analysis for Australian Clinical Labs. The latest half year result and interim dividend have arrived against a weaker backdrop for shareholders, with the share price at A$2.15 after a 30 day share price return decline of 15.35% and a 1 year total shareholder...

SEEK H1 2026 Earnings: Headline Results SEEK (ASX:SEK) has posted its H1 2026 numbers, with investors looking back to the recent H2 2025 performance, where revenue was A$560.8 million and basic EPS came in at A$0.28, alongside net income from ongoing operations of A$98.5 million. The company reported revenue of A$526.1 million in H2 2024 and A$560.8 million in H2 2025, while EPS shifted from a loss of A$0.25 to a profit of A$0.28 over the same halves. This sets the scene for a results season...

Judo Capital Holdings (ASX:JDO) has put up a solid H1 2026 scorecard, with revenue of A$205.6 million and net income of A$59.9 million, translating to basic EPS of A$0.053504 and setting the tone for how the rest of the year might look. The bank has seen revenue move from A$172.1 million in H1 2025 to A$175.3 million in H2 2025 and then to A$205.6 million in H1 2026, while basic EPS has stepped from A$0.036738 to A$0.040714 to A$0.053504 over the same periods, giving investors a clear view of...

Botanix Pharmaceuticals (ASX:BOT) has drawn fresh attention after filing multiple follow on equity offerings totaling A$45 million. The company is issuing new ordinary shares at A$0.06 with attached options that could reshape its capital structure. See our latest analysis for Botanix Pharmaceuticals. That equity raising lands after a sharp reset in sentiment, with a 1 day share price return showing a 41.33% decline at the latest A$0.066 close and a 1 year total shareholder return of 86.80%...

Australian shares are on the rise, bolstered by a strong February reporting season and modest gains on Wall Street, contributing to an optimistic outlook for investors. For those willing to explore beyond the well-known blue-chip stocks, penny stocks—often representing smaller or newer companies—offer intriguing possibilities. While the term may seem outdated, these stocks continue to present opportunities for growth at lower price points when supported by solid financials and fundamentals.

Zip Co (ASX:ZIP) has launched a new brand platform called "In You We Trust". The company has rolled out a national "You Trust Me?" campaign to support the new positioning. Alongside the branding shift, Zip Co is introducing product updates and new app features focused on trust and flexibility. Zip Co operates in digital financial services, where competition from both traditional banks and newer fintechs has been intense. By centering its new platform on trust and customer control, ASX:ZIP...

We'd be surprised if QEM Limited ( ASX:QEM ) shareholders haven't noticed that an insider, Gavin Loyden, recently sold...

Insiders who purchased Micro-X Limited ( ASX:MX1 ) shares in the past 12 months are unlikely to be deeply impacted by...

In the last week, the Australian market has remained flat, but over the past 12 months, it has seen a modest rise of 3.6%, with earnings forecasted to grow by 12% annually. In this environment, selecting dividend stocks with solid yields can be an effective strategy for investors seeking steady income and potential growth in their portfolios.

As Australian shares navigate a modest start to the week amid the bustling February reporting season, investors are keenly observing developments with limited guidance from U.S. and Chinese markets due to their respective holidays. In this environment, growth companies with high insider ownership can offer unique insights into market confidence, as insiders often have a deep understanding of their company's potential and prospects.

As Australian shares prepare for a modest open amid the bustling February reporting season, investors are navigating a market temporarily devoid of guidance from the U.S. and Chinese traders due to respective holidays. In this environment, identifying stocks trading below their estimated intrinsic worth can present valuable opportunities, particularly as companies release their latest financial results and strategic updates.

As Australian shares gear up for a modest open amid the bustling February reporting season, investors are keeping a close watch on the Reserve Bank of Australia's latest policy meeting minutes. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that can offer unique investment opportunities. By focusing on those with solid financial foundations and growth potential, investors might uncover hidden gems in the market.

JB Hi-Fi (ASX:JBH) has kicked off H1 2026 with A$6.1b in revenue and basic EPS of A$2.80, setting the tone for its latest earnings update. The company has seen revenue move from A$5.7b and EPS of A$2.61 in H1 2025 to A$4.9b and A$1.62 in H2 2025, before reaching A$6.1b and A$2.80 in H1 2026. This gives investors a clear view of how sales and EPS have tracked across recent halves. With a trailing net profit margin of 4.4% and steady earnings over the last twelve months, the story now turns to...

BlueScope Steel (ASX:BSL) has kicked off FY26 with H1 revenue of A$8.3b and basic EPS of A$0.88, as investors weigh these headline numbers against a year where margins have come under pressure. The company has seen revenue move from A$7.9b in H1 2025 to A$8.3b in H1 2026, while basic EPS has shifted from A$0.40 to A$0.88 over the same period. This has occurred against a backdrop of modest 3.4% revenue growth, compressed net profit margins at 1.7%, and a large one off loss that dragged on...

Whitefield Income (ASX:WHI) has released its H1 2026 scorecard, with investors watching how the latest A$16.97 million in trailing twelve month revenue and A$13.39 million in net income feed through to EPS of A$0.159634 on a A$1.425 share price. The company has reported revenue of A$2.04 million and EPS of A$0.058984 in H1 2025, followed by A$8.22 million in revenue and EPS of A$0.04039 in H2 2025, contributing to a reported earnings jump of roughly 8x over the past year and a net profit...

Challenger (ASX:CGF) has kicked off H1 2026 with trailing 12 month revenue of A$2.9 billion and basic EPS of A$0.67, while its most recent reported half year, H2 2025, showed revenue of A$1.1 billion and basic EPS of A$0.17. This sets a clear earnings focused backdrop for the latest update. The company has seen revenue move from A$1.3 billion in H2 2024 to A$1.8 billion in H1 2025 and then A$1.1 billion in H2 2025, with basic EPS shifting over the same halves from A$0.11 to A$0.11 and then...

Stockland (ASX:SGP) has reported H1 2026 revenue of A$1.3b and basic EPS of A$0.12, with trailing twelve month revenue of A$3.5b and EPS of A$0.36. These figures frame the latest numbers against a much stronger full year earnings picture, which includes a large one off gain of A$207.0m that helped push earnings growth to 94.9% over the past year. Over recent halves the group has seen revenue move from A$1.0b and EPS of A$0.10 in H1 2025 to A$2.2b and EPS of A$0.24 in H2 2025. This has set the...

Reliance Worldwide (ASX:RWC) has opened H1 2026 reporting with investors focused on how its latest half stacks up against a recent stretch of softer earnings, with the most recent full half year on record showing revenue of US$638.2 million and basic EPS of US$0.074 in H2 2025, compared with US$656.2 million and US$0.075 in H2 2024. Over the past three reported halves, revenue has moved from US$656.2 million in H2 2024 to US$676.5 million in H1 2025 and then to US$638.2 million in H2 2025,...

Baby Bunting Group (ASX:BBN) opened H1 2026 with H2 2025 revenue of A$267.6 million and basic EPS of A$0.042, capped by trailing 12 month revenue of A$539.0 million and EPS of A$0.056. The company has seen revenue move from A$249.9 million in H2 2024 to A$254.4 million in H1 2025 and A$267.6 million in H2 2025, while basic EPS shifted from a loss of A$0.007 in H2 2024 to A$0.029 in H1 2025 and A$0.042 in H2 2025. This sets up a result where modestly higher margins are front and center for...

Deterra Royalties (ASX:DRR) has put up another solid scorecard for H1 2026, with trailing 12 month revenue of A$272.5 million, net income of A$178.9 million and basic EPS of A$0.34, setting a clear benchmark for how the latest half stacks up. Over the last three reported halves, revenue has moved from A$121.5 million in H2 2024 to A$112.3 million in H1 2025 and A$151.1 million in H2 2025, while basic EPS shifted from A$0.14 to A$0.12 and then A$0.17. This gives investors a concrete read on...

Sims (ASX:SGM) has reported H1 2026 results showing revenue of A$3.8b and a basic EPS loss of A$0.155, setting a mixed tone for the half. The company has seen revenue move from A$3.5b in H1 2024 to A$3.8b in H1 2025, while basic EPS shifted from a profit of A$0.510 to a loss of A$0.155, putting the focus firmly on how effectively management is controlling costs and protecting margins. See our full analysis for Sims. With the headline numbers on the table, the next step is to see how this...

Smart Parking (ASX:SPZ) has released its H1 2026 scorecard, with the latest trailing twelve month numbers showing revenue of A$108.1 million and basic EPS of A$0.0142 supported by net income of A$5.8 million. The company has reported revenue of A$27.98 million in H2 2024, A$32.01 million in H1 2025 and A$45.33 million in H2 2025, while basic EPS over those periods came in at A$0.0040, A$0.0112 and A$0.0038 respectively. This provides the backdrop for investors to focus closely on how margins...

Macmahon Holdings (ASX:MAH) has put up another solid set of numbers for H1 2026, with revenue of about A$1.25b and basic EPS of A$0.0206, backed by trailing 12 month revenue of roughly A$2.55b and EPS of A$0.0431 that reflects a 97.2% lift in earnings over the prior year. The company has seen revenue move from A$1.06b in H2 2024 to A$1.18b in H1 2025 and then to A$1.25b in H2 2025, while basic EPS progressed from A$0.0079 to A$0.0141 and then A$0.0206 over the same halves. This sets up a...

Australian Clinical Labs (ASX:ACL) has just posted its H1 2026 numbers, with revenue of A$365.4 million and net income of A$5.6 million translating to basic EPS of A$0.03, setting a measured tone for the half. The company has seen revenue sit in a tight band over the last year, moving from A$369.2 million in H1 2025 to A$372.1 million in H2 2025 and now A$365.4 million, while EPS has changed from A$0.06 in H1 2025 to A$0.12 in H2 2025 and A$0.03 in the latest half, leaving investors focused...